Stigmasterol mitigates inflammation through the suppression of the NF-κB signaling pathway (Ahmad Khan et al., 2020) and impedes cancer cell proliferation and survival by targeting the Akt/mTOR and JAK/STAT pathways (Bakrim et al., 2022). Here, AKT1 is linked to cancer.